China's Ad5-nCoV Vaccine

September 06, 2022
Current Context: China's CanSino Biologics Inc. developed the world's first needle-free COVID-19 Vaccine which can be inhaled.
China's Ad5-nCoV Vaccine
  • CanSino’s Ad5-nCoV Vaccine was given approval by China’s National Medical Products Administration for emergency use as a booster vaccine.
  • Ad5-nCoV is the latest version of CanSino’s one-shot Covid drug which was used by China, Pakistan, Hungary, Mexico, and Malaysia after it was rolled out in February 2021.
  • CanSino said that the inhaled version of the vaccine will trigger cellular immunity by stimulating antibodies in nasal and airway tissues to defend against COVID-19.
  • Many companies around the globe are researching the possibility of needle-free vaccines for other preventable diseases as they could appeal to vaccine-hesitant people.
  • Covaxin is only India's indigenous COVID-19 vaccine which was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Question:

Q.1 The world's first inhaled version of the COVID-19 vaccine has been developed by?
a. China
b. India
c. Germany
d. USA

Free Exam Resources

Useful material to support your preparation, revision and exam planning.

Continue on BankExamsToday

Revise notes, practice questions and resume anytime.

Meet your mentor

From the Founder

Ramandeep Singh, founder of BankExamsToday

Ramandeep Singh

Banking Educator · Former Banker

Former banker and educator helping aspirants prepare for banking promotion and specialist officer exams with focused, practical guidance.

14+
Years' experience
5,000+
Selections
Ex-BoB
Banking experience